

**Supplementary Table 4.** Biomarker Ratios in Patients Who Proceeded to Colectomy Compared to Patients Who Avoided Colectomy by 12 Months, Calculated at Baseline (on Admission), Day 1 Post Infliximab Salvage and Day 3 Post Infliximab Salvage

Biomarker ratios	Colectomy	No colectomy	P-value
Admission			
CAR, mg/g (n = 94)	2.04 (1.05–9.50)	1.52 (0.61–3.58)	0.060
CLR, mg/10 <sup>9</sup> (n = 94)	68.3 (21.4–159.7)	26.0 (12.9–82.6)	0.023
NLR (n = 94)	5.88 (3.43–9.07)	5.15 (3.25–9.70)	0.300
PLR (n = 94)	367.8 (235.3–586.6)	232.2 (154.8–398.0)	0.020
Day 1 post infliximab			
CAR, mg/g (n = 91)	1.29 (0.57–4.80)	0.38 (0.16–0.96)	<0.001
CLR, mg/10 <sup>9</sup> (n = 93)	19.4 (10.8–72.0)	5.8 (2.5–16.1)	<0.001
NLR (n = 93)	5.33 (2.33–7.50)	4.85 (2.72–7.87)	0.850
PLR (n = 93)	295.5 (167.9–373.6)	216.7 (127.0–316.4)	0.190
Day 3 post infliximab			
CAR, mg/g (n = 81)	1.05 (0.48–2.70)	0.18 (0.05–0.43)	<0.001
CLR, mg/10 <sup>9</sup> (n = 84)	19.7 (6.5–40.0)	2.1 (0.7–4.0)	<0.001
NLR (n = 84)	4.57 (3.65–6.95)	2.93 (1.80–4.90)	0.018
PLR (n = 84)	239.6 (186.0–485.4)	127.1 (99.6–233.3)	0.004

Values are presented as median (interquartile range).

CAR, C-reactive protein (CRP)-albumin ratio; CLR, CRP-lymphocyte rate; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio.

Spearman rank correlation  $\rho$  between biomarkers and need for colectomy are given.